Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
gene editing
Advertisement
Precision BioSciences Reveals Breakthrough HBV Data
DURHAM, N.C., May 27, 2026 Precision BioSciences announced new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV,...
Lilly’s VERVE-102 Shows Durable LDL-C Reduction
Indianapolis, Indiana, USA, May 25, 2026 Eli Lilly and Company has announced positive Phase 1b clinical results for VERVE-102,...
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Mission Bio Unveils Single-Cell CRISPR T Cell Data
SOUTH SAN FRANCISCO, Calif., May 2026 Mission Bio announced new data demonstrating the power of its Targeted Single-Cell DNA+RNA...
Advertisements
BioMarin VOXZOGO Shows Long-Term Growth Benefits
San Rafael, California, United States | May 2, 2026 BioMarin Pharmaceutical Inc. has presented new long-term clinical data for...
Scribe Therapeutics Showcases CRISPR and STX-1150 Data
Alameda, California, United States | April 30, 2026 Scribe Therapeutics has announced significant advancements in its engineered CRISPR gene...
Profluent, Lilly Partner to Advance AI Gene Editing Tech
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
Intellia Nears Phase 3 CRISPR Data in HAE Breakthrough
Cambridge, Massachusetts | April 24, 2026 Intellia Therapeutics has announced a pivotal milestone in genetic medicine, confirming that it...
Fate Therapeutics FT839 CAR T Shows Strong Preclinical Data
SAN DIEGO, Calif., April 16, 2026 Fate Therapeutics, Inc. has announced the presentation of preclinical data for its next-generation...
Advertisement
